Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease
Catheterization and Cardiovascular Interventions · 2023
DOI: 10.1002/ccd.30878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2023. Verfasst von Ioannis Merinopoulos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, UK. Hauptthemen laut MEDLINE: Coronary Artery Disease, Drug-Eluting Stents, Angioplasty, Balloon, Coronary, Coronary Restenosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute for Health Research Capability Fund from Norfolk and Norwich University Hospital, B. Braun Medical.
Abstract (Originalsprache)
Aims
We aimed to perform a cost analysis of drug coated balloon (DCB)‐only angioplasty versus drug eluting stent (DES), for de novo disease of all vessel sizes and all clinical indications.
Background
DCB angioplasty is an emergent technology for the treatment of coronary artery disease. There is lack of data regarding the cost‐effectiveness of DCB‐only angioplasty for treatment of de novo coronary artery disease as compared with second generation DES.
Methods
We compared total costs of patients treated with DCB or DES for first presentation of ST‐elevation myocardial infarction, non‐ST‐elevation myocardial infarction, or stable angina due to de novo disease between January 1, 2018 and November 15, 2019. We defined total cost as the sum of (1) procedural devices‐cost, (2) procedural staff‐cost, (3) post‐percutaneous coronary intervention hospital stay cost, and (4) antiplatelet regime cost. A cost minimization analysis was performed to compare the costs of DCB and DES.
Results
We present 1952 all‐comer, consecutive patients; 902 (1064 lesions) treated with DCB and 1050 (1236 lesions) treated with DES for de novo coronary artery disease. The cost per patient was estimated to be £9.02 more expensive in the DCB group (£3153.00 vs. £3143.98). However, the cost per lesion treated was calculated to be £15.51 cheaper in the DCB group (£3007.56 vs. £3023.07). The results were consistent irrespective of duration of long‐term antiplatelet medications.
Conclusion
We have compared the cost‐effectiveness of DCB‐only angioplasty to DES‐angioplasty and showed that the per patient and per lesion results were not different and hence cost should not be implicated in the decision to choose DCB or DES.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, UK.
- Norwich Medical School, University of East Anglia, Norwich, UK.
ORCID-Profile: Ioannis Merinopoulos, Vassilios Vassiliou
Förderung
- National Institute for Health Research Capability Fund from Norfolk and Norwich University Hospital
- B. Braun Medical
Zitieren
APA
Merinopoulos, I., Gunawardena, T., Corballis, N., Tsampasian, V., Vassiliou, V., Eccleshall, S., Ryding, A., & Xydopoulos, G. (2023). Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30878
Vancouver
Merinopoulos I, Gunawardena T, Corballis N, Tsampasian V, Vassiliou V, Eccleshall S, et al. Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease. Catheterization and Cardiovascular Interventions. 2023. doi:10.1002/ccd.30878
BibTeX
@article{Merinopoulos2023,
author = {Merinopoulos, Ioannis and Gunawardena, Tharusha and Corballis, Natasha and Tsampasian, Vasiliki and Vassiliou, Vassilios and Eccleshall, Simon and Ryding, Alisdair and Xydopoulos, George},
title = {Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease},
journal = {Catheterization and Cardiovascular Interventions},
year = {2023},
doi = {10.1002/ccd.30878}
}
EUVIMED